Towers GJ - Search Results

1

Anti-type I interferon antibodies as a cause of severe COVID-19.

Fajgenbaum DC, Hayday AC, Rogers AJ, Towers GJ, Wack A, Zanoni I. Fajgenbaum DC, et al. Among authors: towers gj. Fac Rev. 2022 Jun 10;11:15. doi: 10.12703/r-01-0000010. eCollection 2022. Fac Rev. 2022. PMID: 35812362 Free PMC article.

2

Innate immune interferon responses to human immunodeficiency virus-1 infection.

Hughes R, Towers G, Noursadeghi M. Hughes R, et al. Rev Med Virol. 2012 Jul;22(4):257-66. doi: 10.1002/rmv.1708. Epub 2012 Feb 22. Rev Med Virol. 2012. PMID: 22359246 Review.

3

Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants.

Reuschl AK, Thorne LG, Whelan MVX, Ragazzini R, Furnon W, Cowton VM, De Lorenzo G, Mesner D, Turner JLE, Dowgier G, Bogoda N, Bonfanti P, Palmarini M, Patel AH, Jolly C, Towers GJ. Reuschl AK, et al. Among authors: towers gj. Nat Microbiol. 2024 Feb;9(2):451-463. doi: 10.1038/s41564-023-01588-4. Epub 2024 Jan 16. Nat Microbiol. 2024. PMID: 38228858 Free PMC article.

4

Influence of gag on human immunodeficiency virus type 1 species-specific tropism.

Ikeda Y, Ylinen LM, Kahar-Bador M, Towers GJ. Ikeda Y, et al. Among authors: towers gj. J Virol. 2004 Nov;78(21):11816-22. doi: 10.1128/JVI.78.21.11816-11822.2004. J Virol. 2004. PMID: 15479823 Free PMC article.

5

Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles.

Ylinen LM, Keckesova Z, Wilson SJ, Ranasinghe S, Towers GJ. Ylinen LM, et al. Among authors: towers gj. J Virol. 2005 Sep;79(18):11580-7. doi: 10.1128/JVI.79.18.11580-11587.2005. J Virol. 2005. PMID: 16140735 Free PMC article.

6

Retroviral restriction factors Fv1 and TRIM5alpha act independently and can compete for incoming virus before reverse transcription.

Passerini LD, Keckesova Z, Towers GJ. Passerini LD, et al. Among authors: towers gj. J Virol. 2006 Mar;80(5):2100-5. doi: 10.1128/JVI.80.5.2100-2105.2006. J Virol. 2006. PMID: 16474118 Free PMC article.

7

Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity.

Keckesova Z, Ylinen LM, Towers GJ. Keckesova Z, et al. Among authors: towers gj. J Virol. 2006 May;80(10):4683-90. doi: 10.1128/JVI.80.10.4683-4690.2006. J Virol. 2006. PMID: 16641261 Free PMC article.

8

Isolation of an active Lv1 gene from cattle indicates that tripartite motif protein-mediated innate immunity to retroviral infection is widespread among mammals.

Ylinen LM, Keckesova Z, Webb BL, Gifford RJ, Smith TP, Towers GJ. Ylinen LM, et al. Among authors: towers gj. J Virol. 2006 Aug;80(15):7332-8. doi: 10.1128/JVI.00516-06. J Virol. 2006. PMID: 16840314 Free PMC article.

9

Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells.

Noser JA, Towers GJ, Sakuma R, Dumont JM, Collins MK, Ikeda Y. Noser JA, et al. Among authors: towers gj. J Virol. 2006 Aug;80(15):7769-74. doi: 10.1128/JVI.02427-05. J Virol. 2006. PMID: 16840358 Free PMC article.

10

The control of viral infection by tripartite motif proteins and cyclophilin A.

Towers GJ. Towers GJ. Retrovirology. 2007 Jun 12;4:40. doi: 10.1186/1742-4690-4-40. Retrovirology. 2007. PMID: 17565686 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

129 results

Search Page